“We continue to believe that a multi-billion-dollar market opportunity awaits, and we estimate that GNMK is ~2% penetrated and is likely to achieve at least ~10% market share of syndromic test panel testing over time. We reiterate our $10 PT, which uses a 5.7x multiple on our 2020 rev. estimate of $108M, discounted back 1 year at a 12% discount rate.”
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.7% and a 60.3% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Currently, the analyst consensus on GenMark is a Moderate Buy with an average price target of $11.
Based on GenMark’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $11.56 million. In comparison, last year the company had a GAAP net loss of $11.42 million.
Based on the recent corporate insider activity of 93 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which engages in the provision of multiplex molecular diagnostic solutions. Its products include ePlex and XT-8. The company was founded by Jon Faiz Kayyemin 1993 and is headquartered in Carlsbad, CA.